Clinical Trials

A Phase III Randomized, Double-Blind Study of Maintenance Therapy with
CC-5013 or Placebo Following Autologous Stem Cell Transplantation for Multiple Myeloma

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia

A Randomized Phase II Study of Three Fludarabine/Antibody Combinations for Patients with Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia

A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PKC412) or Placebo in Newly Diagnosed Patients
< 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia (AML)

A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-Small Cell Lung Cancer

A Phase III Double Blind Trial of Oral Duloxetine for Treatment of Pain
Associated with Chemotherapy-Induced Peripheral Neuropathy (CIPN)

AML Companion-Novel markers

Combination Cisplatin, Etoposide and Sunitinib for Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/II Study

Temp clos 7/21/10
A Randomized Phase III Trial of Adjuvant Therapy in Early Stage Non-Small Cell Lung Cancer Evaluating the Potential Utility of a Genomic Prognostic Model to Identify Patients as Candidates for Adjuvant Chemotherapy

A Phase II Study of Induction Chemotherapy Followed by Thoracic Radiotherapy and Erlotinib in Poor-Risk Stage III Non-Small Cell Lung Cancer

Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced,
Stage IIIB/IV Non-Small Cell Lung Cancer

Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer also Receiving Cisplatin and Etoposide

A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed plus Sunitinib in the Second-Line Treatment of Advanced Non-Small Cell Lung Cancer

A Randomized Phase III Double Blind Trial Evaluating Selective Cox-2 Inhibition In Cox-2 Expressing Advanced Non-Small Cell Lung Cancer

Randomized Phase II Study of Maintenance Pemetrexed versus Observation for Patients with Malignant Pleural Mesothelioma without Progression after
First-Line Chemotherapy

A Randomized Phase III Trial of Weekly Paclitaxel Compared to Weekly Nanoparticle Albumin Bound Nab-Paclitaxel or Ixabepilone
Combined with Bevacizumab as First-Line Therapy for Locally Recurrent or Metastatic Breast Cancer

Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab For Women with Hormone Receptor-Positive Advanced Breast Cancer

Randomized Phase III Trial of Paclitaxel Combined with Trastuzumab, Lapatinib or Both as Neoadjuvant Treatment of HER2-Positive Primary Breast Cancer

Randomized Phase II 2x2 Factorial Trial of the Addition of Carboplatin and/or Bevacizumab To Neoadjuvant Weekly Paclitaxel Followed by Dose-Dense AC in Hormone Receptor-Poor/HER2-Negative Resectable Breast Cancer

Phase III Randomized Study of R-CHOP vs Dose-Adjusted EPOCH-R with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas

A Randomized Phase II Trial of Rituximab vs. Lenalidomide (Revlimid™ or CC-5013) vs. Rituximab plus Lenalidomide in Recurrent Follicular Non-Hodgkin’s Lymphoma (NHL) After Relapse from a Rituximab-Containing Combination Regimen

A Phase II Trial of Bortezomib (Velcade) plus Lenalidomide(Revlimid™ or CC-5013) for Relapsed/Refractory Mantle Cell Lymphoma

Phase II Trial of Response-Adapted Therapy based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical
Hodgkin Lymphoma (HL)

Phase II Trial of Response-Adapted Chemotherapy Based on Positron Emission Tomography for Non-Bulky Stage I and II Hodgkin Lymphoma

Quality of Life, Employment and Informal Care Cost Analysis in Women Receiving Adjuvant Chemotherapy for Breast Cancer with 0-3
Positive Axillary Lymph Nodes